These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 37366661)

  • 1. Rivaroxaban-loaded SLNs with treatment potential of deep vein thrombosis: in-vitro, in-vivo, and toxicity evaluation.
    Luo X; Saleem A; Shafique U; Sarwar S; Ullah K; Imran M; Zeb A; Din FU
    Pharm Dev Technol; 2023 Sep; 28(7):625-637. PubMed ID: 37366661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced Biopharmaceutical Performance of Rivaroxaban through Polymeric Amorphous Solid Dispersion.
    Metre S; Mukesh S; Samal SK; Chand M; Sangamwar AT
    Mol Pharm; 2018 Feb; 15(2):652-668. PubMed ID: 29287144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel rivaroxaban-loaded poly(lactic-co-glycolic acid)/poloxamer nanoparticles: preparation, physicochemical characterization, in vitro evaluation of time-dependent anticoagulant activity and toxicological profile.
    Machado ME; de Souza Furtado P; da Costa Bernardes Araújo C; Simon A; de Moraes MC; Rodrigues Pereira da Silva LC; do Carmo FA; Cabral LM; Sathler PC
    Nanotechnology; 2021 Mar; 32(13):135101. PubMed ID: 33276347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: characterization, pharmacokinetic and pharmacodynamic evaluation.
    Dudhipala N; Veerabrahma K
    Drug Deliv; 2016; 23(2):395-404. PubMed ID: 24865287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained release and enhanced oral bioavailability of rivaroxaban by PLGA nanoparticles with no food effect.
    Anwer MK; Mohammad M; Iqbal M; Ansari MN; Ezzeldin E; Fatima F; Alshahrani SM; Aldawsari MF; Alalaiwe A; Alzahrani AA; Aldayel AM
    J Thromb Thrombolysis; 2020 Apr; 49(3):404-412. PubMed ID: 31898270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of Dose Proportionality of Rivaroxaban Nanocrystals.
    Demir H; Gulsun T; Ozkan MH; Nemutlu E; Sahin S; Öner L
    AAPS PharmSciTech; 2020 Aug; 21(6):228. PubMed ID: 32767034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Raloxifene-loaded SLNs with enhanced biopharmaceutical potential: QbD-steered development, in vitro evaluation, in vivo pharmacokinetics, and IVIVC.
    Jain A; Sharma T; Kumar R; Katare OP; Singh B
    Drug Deliv Transl Res; 2022 May; 12(5):1136-1160. PubMed ID: 33966178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fabrication of solid lipid nanoparticles of lurasidone HCl for oral delivery: optimization,
    Patel MH; Mundada VP; Sawant KK
    Drug Dev Ind Pharm; 2019 Aug; 45(8):1242-1257. PubMed ID: 30880488
    [No Abstract]   [Full Text] [Related]  

  • 9. Enhanced Oral Absorption of All-trans Retinoic Acid upon Encapsulation in Solid Lipid Nanoparticles.
    Kumar M; Sharma G; Singla D; Singh S; Kakkar V; Gulati JS; Kaur IP
    Pharm Nanotechnol; 2020; 8(6):495-510. PubMed ID: 33115399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Naringenin-loaded solid lipid nanoparticles: preparation, controlled delivery, cellular uptake, and pulmonary pharmacokinetics.
    Ji P; Yu T; Liu Y; Jiang J; Xu J; Zhao Y; Hao Y; Qiu Y; Zhao W; Wu C
    Drug Des Devel Ther; 2016; 10():911-25. PubMed ID: 27041995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nano-formulation of rifampicin with enhanced bioavailability: development, characterization and in-vivo safety.
    Singh H; Jindal S; Singh M; Sharma G; Kaur IP
    Int J Pharm; 2015 May; 485(1-2):138-51. PubMed ID: 25769294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of lipid-based nanoparticles for enhancing the oral bioavailability of paclitaxel.
    Pandita D; Ahuja A; Lather V; Benjamin B; Dutta T; Velpandian T; Khar RK
    AAPS PharmSciTech; 2011 Jun; 12(2):712-22. PubMed ID: 21637945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of Domperidone Solid Lipid Nanoparticles: In Vitro and In Vivo Characterization.
    Shazly GA; Alshehri S; Ibrahim MA; Tawfeek HM; Razik JA; Hassan YA; Shakeel F
    AAPS PharmSciTech; 2018 May; 19(4):1712-1719. PubMed ID: 29532427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced Oral Bioavailability of Rivaroxaban-Loaded Microspheres by Optimizing the Polymer and Surfactant Based on Molecular Interaction Mechanisms.
    Choi MJ; Woo MR; Baek K; Park JH; Joung S; Choi YS; Choi HG; Jin SG
    Mol Pharm; 2023 Aug; 20(8):4153-4164. PubMed ID: 37433746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Formulation, Characterization, and Evaluation of Eudragit-Coated Saxagliptin Nanoparticles Using 3 Factorial Design Modules.
    Alhamhoom Y; Ravi G; Osmani RAM; Hani U; Prakash GM
    Molecules; 2022 Nov; 27(21):. PubMed ID: 36364338
    [No Abstract]   [Full Text] [Related]  

  • 16. Formulation design, preparation and physicochemical characterizations of solid lipid nanoparticles containing a hydrophobic drug: effects of process variables.
    Das S; Ng WK; Kanaujia P; Kim S; Tan RB
    Colloids Surf B Biointerfaces; 2011 Nov; 88(1):483-9. PubMed ID: 21831615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipid-Based Gliclazide Nanoparticles for Treatment of Diabetes: Formulation, Pharmacokinetics, Pharmacodynamics and Subacute Toxicity Study.
    Nazief AM; Hassaan PS; Khalifa HM; Sokar MS; El-Kamel AH
    Int J Nanomedicine; 2020; 15():1129-1148. PubMed ID: 32110012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic and pharmacodynamic studies of nisoldipine-loaded solid lipid nanoparticles developed by central composite design.
    Dudhipala N; Veerabrahma K
    Drug Dev Ind Pharm; 2015; 41(12):1968-77. PubMed ID: 25830370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mannosylated Solid Lipid Nanocarriers of Chrysin to Target Gastric Cancer: Optimization and Cell Line Study.
    Pandey SS; Shaikh FI; Gupta AR; Vaidya RJ
    Curr Drug Deliv; 2021; 18(10):1574-1584. PubMed ID: 33745434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, characterization and in vivo performance of solid lipid nanoparticles (SLNs)-loaded mucoadhesive buccal tablets for efficient delivery of Lornoxicam in experimental inflammation.
    Zewail MB; F Asaad G; Swellam SM; Abd-Allah SM; K Hosny S; Sallah SK; E Eissa J; S Mohamed S; El-Dakroury WA
    Int J Pharm; 2022 Aug; 624():122006. PubMed ID: 35820515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.